Berry Leanne,Phillips Gail Lewis,Sliwkowski Mark X.
申请号：
SI200931689
公开号：
SI2644194T1
申请日:
2009.03.10
申请国别(地区):
SI
年份:
2017
代理人:
摘要：
Combinations of the antibody-drug conjugate trastuzumab-MCC-DM 1 and pertuzumab, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro , in situ , and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
